Alphamab Oncology's KN026 NDA for HER2+ Gastric Cancer Accepted by China's NMPA, Achieving Breakthrough Therapy Designation and Priority Review Status
I'm PortAI, I can summarize articles.
Alphamab Oncology's new drug application (NDA) for KN026, an Anbenitamab injection for HER2-positive gastric cancer, has been accepted by China's NMPA. The NDA, supported by a pivotal clinical trial, aims to treat patients who have failed prior therapies. KN026 has received breakthrough therapy designation and priority review status, marking it as the first anti-HER2 bispecific antibody for second-line treatment in this context. Currently, there are no approved anti-HER2 therapies for this indication.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments